Literature DB >> 12354876

Multicenter evaluation of a nonweekend reading schedule for radiometric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

B Madison1, W Gross, I George, A Sloutsky, G Washabaugh, B Robinson-Dunn, H Lipman, B Metchock, G Mazurek, J Ridderhof.   

Abstract

Pyrazinamide (PZA) is an integral component of the short-course chemotherapy regimen for tuberculosis. The BACTEC 460TB PZA susceptibility test for Mycobacterium tuberculosis with a daily (D) reading schedule has been available for more than 10 years, but weekend laboratory staffing is necessary. A nonweekend (NW) reading schedule has not been validated in a multicenter study. This prospective multicenter study compares the interlaboratory reproducibility of PZA susceptibility results by following both the D and NW schedules. A total of 181 cultures were shared among four laboratories. Isolates were selected based on resistance or borderline resistance to at least one streptomycin-isoniazid-rifampin-ethambutol drug or PZA. One laboratory used a D reading schedule, and three laboratories used a NW schedule. Both reading schedules are based on the standard BACTEC 460TB PZA protocol. With the NW schedule, the growth index (GI) is not available for test interpretation on Saturday, Sunday, and Monday. Of the 181 shared cultures, 154 were found to be susceptible by all laboratories, 19 were found to be resistant, and 8 had discordant results. The overall pairwise interlaboratory agreement was 97.7%. The discrepancies were not associated with the type of reading schedule used. However, the median control GI was significantly higher for the NW schedule (321) than for the D schedule (259) (P < 0.0001) although results were available on average in about 7 days from setup for both schedules. These results show that the NW schedule is a suitable alternative for laboratories that do not read and interpret PZA susceptibility tests on weekends.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354876      PMCID: PMC130879          DOI: 10.1128/JCM.40.10.3753-3756.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Ying Zhang; Sallie Permar; Zhonghe Sun
Journal:  J Med Microbiol       Date:  2002-01       Impact factor: 2.472

2.  New agar medium for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  L Heifets; T Sanchez
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  Nonweekend schedule for BACTEC drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  J E Hawkins
Journal:  J Clin Microbiol       Date:  1986-05       Impact factor: 5.948

4.  Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar.

Authors:  K D Stottmeier; R E Beam; G P Kubica
Journal:  Am Rev Respir Dis       Date:  1967-11

5.  Simple pyrazinamidase and urease tests for routine identification of mycobacteria.

Authors:  L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-01

6.  Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.

Authors:  C Raynaud; M A Lanéelle; R H Senaratne; P Draper; G Lanéelle; M Daffé
Journal:  Microbiology       Date:  1999-06       Impact factor: 2.777

7.  Evaluation of a radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  J J Tarrand; A D Spicer; D H Gröschel
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Direct antimicrobial drug susceptibility testing of Mycobacterium tuberculosis by the radiometric method.

Authors:  J P Libonati; C E Stager; J R Davis; S H Siddiqi
Journal:  Diagn Microbiol Infect Dis       Date:  1988-05       Impact factor: 2.803

9.  Improved method for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  W R Butler; J O Kilburn
Journal:  J Clin Microbiol       Date:  1982-12       Impact factor: 5.948

10.  Radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis in egg-yolk-enriched BACTEC 12A medium.

Authors:  C L Woodley; R W Smithwick
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more
  2 in total

1.  Msx1 loss suppresses formation of the ectopic crypts developed in the Apc-deficient small intestinal epithelium.

Authors:  Monika Horazna; Lucie Janeckova; Jiri Svec; Olga Babosova; Dusan Hrckulak; Martina Vojtechova; Katerina Galuskova; Eva Sloncova; Michal Kolar; Hynek Strnad; Vladimir Korinek
Journal:  Sci Rep       Date:  2019-02-07       Impact factor: 4.379

2.  Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss.

Authors:  Chawangwa Modongo; Rafal S Sobota; Boikobo Kesenogile; Ronald Ncube; Giorgio Sirugo; Scott M Williams; Nicola M Zetola
Journal:  BMC Infect Dis       Date:  2014-10-09       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.